KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Revenue (2016 - 2025)

Pfizer (PFE) has disclosed Revenue for 17 consecutive years, with $31.9 billion as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 185.16% to $31.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $62.6 billion, a 411.52% increase, with the full-year FY2025 number at $62.6 billion, up 646.05% from a year prior.
  • Revenue was $31.9 billion for Q4 2025 at Pfizer, up from $2.3 billion in the prior quarter.
  • In the past five years, Revenue ranged from a high of $31.9 billion in Q4 2025 to a low of -$37.5 billion in Q4 2024.
  • A 5-year average of $10.3 billion and a median of $13.6 billion in 2023 define the central range for Revenue.
  • Peak YoY movement for Revenue: tumbled 1191.32% in 2024, then skyrocketed 608.85% in 2025.
  • Pfizer's Revenue stood at $3.4 billion in 2021, then fell by 4.65% to $3.3 billion in 2022, then rose by 5.31% to $3.4 billion in 2023, then crashed by 1191.32% to -$37.5 billion in 2024, then surged by 185.16% to $31.9 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Revenue are $31.9 billion (Q4 2025), $2.3 billion (Q3 2025), and $14.7 billion (Q2 2025).